GSK3B and Alzheimer disease: Inhibiting GSK3β to activate the Wnt/β-catenin pathway has been proposed as a promising therapeutic avenue and is currently under many active investigations; however, targeting the GSK3β pathway for AD has hitherto presented challenges in clinical settings due to small-molecule inhibitor specificity [8].